John B Buse MD, PhD discusses Conclusion and Clinical Implications during Cardiovascular Safety of Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) Trial Results
San Diego, CA - ADA 2017 - Attendees during John B Buse MD, PhD discusses Conclusion and Clinical Implications during Cardiovascular Safety of Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) Trial Results at the American Diabetes Association's 77th Annual Meeting here today, Monday June 12, 2017. More than 16,000 physicians, researchers, health care professionals and patient advocates are expected to attend the 77th Annual Meeting which highlights the latest findings in all major areas of the diabetes research and treatment field. Photo by © ADA/Rodney White 2017 Contact Info: todd@medmeetingimages.com
17ADAMONRWHITE005051Attendees during John B Buse MDPhD discusses Conclusion and Clinical Implications during Cardiovascular Safety of Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events DEVOTE Trial Results
Log In: